Nerve growth factor inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Nerve growth factor inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nerve growth factor inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nerve growth factor inhibitors: Overview
Nerve growth factor (NGF) is an insulin-like protein, which regulates growth, development and maintenance of sympathetic and embryonic sensory neurons.
Function - NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons). In fact, NGF is critical for the survival and maintenance of sympathetic and sensory neurons, as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.
Nerve growth factor inhibitors - NGF is involved in pain signalling. The exact role of NGF signalling in chronic pain is not fully understood, and multiple mechanisms are thought to be involved. NGF is released by immune cells in response to peripheral injury, and is thought to promote neural sensitisation, and neural sprouting. Elevated NGF levels are seen in those with chronic pain conditions (including interstitial cystitis, prostatitis, arthritis, pancreatitis, chronic headaches, cancer pain, and diabetic neuropathy, and injection of NGF causes allodynia and hyperalgesia. NGF inhibitors may take the form of monoclonal antibodies that bind to NGF, or small molecule inhibitors of NGF receptors. NGF inhibition may be achieved by sequestering free NGF molecules, blocking receptor binding, or inhibiting receptor function. Anti-NGF antibodies have demonstrated the greatest promise as potential medications.
Nerve growth factor inhibitors Emerging Drugs Chapters
This segment of the Nerve growth factor inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nerve growth factor inhibitors Emerging Drugs
Further product details are provided in the report……..
Nerve growth factor inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Nerve growth factor inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Nerve growth factor inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nerve growth factor inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nerve growth factor inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Nerve growth factor inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nerve growth factor inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nerve growth factor inhibitors: Overview
Nerve growth factor (NGF) is an insulin-like protein, which regulates growth, development and maintenance of sympathetic and embryonic sensory neurons.
Function - NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons). In fact, NGF is critical for the survival and maintenance of sympathetic and sensory neurons, as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.
Nerve growth factor inhibitors - NGF is involved in pain signalling. The exact role of NGF signalling in chronic pain is not fully understood, and multiple mechanisms are thought to be involved. NGF is released by immune cells in response to peripheral injury, and is thought to promote neural sensitisation, and neural sprouting. Elevated NGF levels are seen in those with chronic pain conditions (including interstitial cystitis, prostatitis, arthritis, pancreatitis, chronic headaches, cancer pain, and diabetic neuropathy, and injection of NGF causes allodynia and hyperalgesia. NGF inhibitors may take the form of monoclonal antibodies that bind to NGF, or small molecule inhibitors of NGF receptors. NGF inhibition may be achieved by sequestering free NGF molecules, blocking receptor binding, or inhibiting receptor function. Anti-NGF antibodies have demonstrated the greatest promise as potential medications.
Nerve growth factor inhibitors Emerging Drugs Chapters
This segment of the Nerve growth factor inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nerve growth factor inhibitors Emerging Drugs
- Tanezumab: Eli Lilly and Company
- Fasinumab: Mirati Therapeutics
Further product details are provided in the report……..
Nerve growth factor inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Nerve growth factor inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Nerve growth factor inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Nerve growth factor inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nerve growth factor inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nerve growth factor inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nerve growth factor inhibitors R&D. The therapies under development are focused on novel approaches for Nerve growth factor inhibitors.
- Nerve growth factor inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Nerve growth factor inhibitors drugs?
- How many Nerve growth factor inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Nerve growth factor inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nerve growth factor inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nerve growth factor inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Mitsubishi Tanabe Pharma
- Regeneron Pharmaceuticals
- Spine Biopharma
- Ensol Biosciences
- Astellas Pharma
- Tanezumab
- Fasinumab
- YH 14618
- Engedi 1000
- ASP 6294
Introduction
Executive Summary
Nerve growth factor inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nerve growth factor inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nerve growth factor inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nerve growth factor inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Tanezumab: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Engedi 1000: Ensol Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nerve growth factor inhibitors Key Companies
Nerve growth factor inhibitors Key Products
Nerve growth factor inhibitors- Unmet Needs
Nerve growth factor inhibitors- Market Drivers and Barriers
Nerve growth factor inhibitors- Future Perspectives and Conclusion
Nerve growth factor inhibitors Analyst Views
Nerve growth factor inhibitors Key Companies
Appendix
Executive Summary
Nerve growth factor inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nerve growth factor inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nerve growth factor inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nerve growth factor inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Tanezumab: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Engedi 1000: Ensol Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nerve growth factor inhibitors Key Companies
Nerve growth factor inhibitors Key Products
Nerve growth factor inhibitors- Unmet Needs
Nerve growth factor inhibitors- Market Drivers and Barriers
Nerve growth factor inhibitors- Future Perspectives and Conclusion
Nerve growth factor inhibitors Analyst Views
Nerve growth factor inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nerve growth factor inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nerve growth factor inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nerve growth factor inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nerve growth factor inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
